# Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

> **NCT04617847** · PHASE1,PHASE2 · TERMINATED · sponsor: **Wave Life Sciences Ltd.** · enrollment: 27 (actual)

## Conditions studied

- Huntington Disease

## Interventions

- **DRUG:** WVE-120101

## Key facts

- **NCT ID:** NCT04617847
- **Lead sponsor:** Wave Life Sciences Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-13
- **Primary completion:** 2021-05-03
- **Final completion:** 2021-05-03
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2022-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04617847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04617847, "Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04617847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*